<?xml version="1.0" encoding="UTF-8"?>
<p id="Par71">It has only been in recent years that harnessing the immune system in the fight against cancer has become well appreciated, especially with respect to therapy of NSCLC [
 <xref ref-type="bibr" rid="CR42">42</xref>â€“
 <xref ref-type="bibr" rid="CR46">46</xref>]. BTH1677 is a novel PAMP molecule capable of inducing coordinated innate and adaptive immune responses. BTH1677 is being developed for the treatment of cancer in combination with tumor-targeted, anti-angiogenic, and checkpoint inhibitor antibodies. Here we report the effects of BTH1677 combined with the anti-angiogenic MAb, bevacizumab, and platinum-based chemotherapy in first-line treatment of advanced non-squamous NSCLC patients.
</p>
